NCT07210723View on ClinicalTrials.gov

A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

332

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

January 31, 2028

Conditions
Symptomatic Genetic Dilated Cardiomyopathy
Interventions
DRUG

danicamtiv

Danicamtiv will be administrated twice daily for up to 26 weeks

DRUG

Placebo

Placebo will be administrated twice daily for up to 26 weeks

Sponsors

Lead Sponsor

Kardigan, Inc.
All Listed Sponsors
lead

Kardigan, Inc.

INDUSTRY

NCT07210723 - A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy | Biotech Hunter | Biotech Hunter